Therapie des Typ-2-Diabetes

Dirk Müller-Wieland; Nikolaus Marx

doi:10.1055/a-0983-0379

DMW - Deutsche Medizinische Wochenschrift, Table of Contents

Dtsch Med Wochenschr 2020; 145(09): 593-600
DOI: 10.1055/a-0983-0379

Dossier

Therapie des Typ-2-Diabetes

Empfehlungen der Europäischen Diabetes-Gesellschaft (EASD)Therapy of type 2 diabetes Recommendations of the European Association for the Study of Diabetes (EASD)

Dirk Müller-Wieland

,

Nikolaus Marx

Abstract

New joint clinical recommendations for the treatment of patients with type 2 diabetes of the european (EASD) and american (ADA) diabetes associations and the european society for cardiology (ESC) implement the evidence from clinical cardiovascular endpoint studies into daily clinical practice. The individual patient profile and it´s cardiovascular risk rather than HbA_1c levels alone dominate treatment strategies. In case of high oder very high cardiovascular risk GLP-1-receptor agonists or SGLT-2-inhibitors are the preferred choice, the latter especially in patients with chronic heart failure or increased risk, respectively.

Auf der Jahrestagung der Europäischen Diabetes-Gesellschaft (EASD) 2018 wurden die gemeinsamen Empfehlungen der EASD zur Behandlung von Patienten mit Typ-2-Diabetes zusammen mit der Amerikanischen Diabetes-Gesellschaft (ADA) verabschiedet. Eine Modifizierung wurde 2019 von der Europäischen Gesellschaft für Kardiologie (ESC) in Kooperation mit der EASD empfohlen. Der Beitrag stellt die wesentlichen Punkte und Hintergründe dieser Veröffentlichungen vor.

Schlüsselwörter

Typ-2-Diabetes - GLP-1-Rezeptoragonisten - SGLT-2-Hemmer - evidenzbasierte Therapie

Key words

type 2 diabetes - GLP-1-Receptor agonists - SGLT-2-Inhibitors - evidence-based therapy

Full Text

References

Literatur
1 Davies MJ, D‘Alessio DA, Fradkin J. et al Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes EASD. Diabetologia 2018; 61: 2461-2498 . Diabetes Care 2018; 41: 2669–2701
2 American Diabetes Association. Standards in Medical Care in Diabetes – 2019. Pharmacological Approaches to glycaemic treatment. Diabetes Care 2019; 42 (Suppl. 01) S90-S102
3 Landgraf R, Aberle J, Birkenfeld AL. et al. Therapie des Typ-2-Diabetes. Diabetologie und Stoffwechsel 2019; 14 (Suppl. 02) S167-S187
4 Consentino F, Grant PJ, Aboyans V. et al. 2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J 2019;
5 Nichols GA, Gullion CM, Koro CE. et al. The incidence of congestive heart failure in type 2 diabetes: an update. Diabetes Care 2004; 27: 1879-1884
6 Wanner C, Marx N. SGLT-2 inhibitors: the future treatment of type 2 diabetes mellitus and other chronic diseases. Diabetologia 2018; 61: 2134-2139
7 Rosenstock J, Kahn SE, Johansen E. et al. Effect of linagliptin vs glimepiride on major adverse cardiovascular outcomes in patients with type 2 diabetes. JAMA 2019; 322: 1155-1166
8 Farell B, Black C, Thompson W. et al. Deprescribing antihyperglycemic agents in older persons. Evidence-based clinical practice guidelines. Can Fam Physician 2017; 63: 832-843
9 Müller-Wieland D, Ickrath M, Bitzer B. Digitale Transformation in der Diabetologie?. In: Kellerer M, Kröger J. Hrsg Gesundheitsbericht Diabetes 2020. Mainz: Kirchheim-Verlag; 2019: 34-40
10 Zinman B, Wanner C, Lachin JM. et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015; 373: 2117-2128
11 Neal B, Perkovic V, Mahaffey KW. et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 2017; 377: 644-657
12 Wiviott SD, Raz I, Bonaca MP. et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2019; 380: 347-357
13 Perkovic V, Jardine MJ, Neal B. et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 2019; 380: 2295-2306
14 Marso SP, Daniels GH, Brown-Frandsen K. et al. Liraglutide and cardiovascular outcomes in patients with type 2 diabetes. New Engl J Med 2016; 375: 311-322
15 Marso SP, Bain SC, Consoli A. et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. New Engl J Med 2016; 375: 1834-1844
16 Hernandez AF, Green JB, Janmohamed S. et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlles trial. Lancet 2018; 392: 1519-1529
17 Gerstein HC, Colhoun HM, Dagenais GR. et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet 2019; 394: 121-130
18 Zinman B, Genuth S, Nathan DM. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study: 30th Aniversay Presentations. Diabetes Care 2014; 37: 8
19 McMurray JJV, Solomon SD, Inzucchi SE. et al. Dapagliflozin in patients with heart failure and reduced rejection fraction. N Engl J Med 2019;
20 Ahlqvist E, Tuomi T, Groop L. Clusters provide a better holistic view of type 2 diabetes than simple clinical features. Lancet Diabetes Endocrinol 2019; 7: 668-669
21 Buse JB, Wexler DJ, Tsapas A. et al 2019 update to: Mangement of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association fort he Study of Diabetes (EASD). Diabetologia 2020; 63: 221-228 und Diabetes Care 2020; 43: 487–493
22 American Diabetes Association. Standards in Medical Care in Diabetes – 2020. Pharmacological Approaches to glycaemic treatment. Diabetes Care 2019; 43: S98-S110